|Over a week ago|
Ziopharm appoints James Huang to board of directors » 08:4207/2207/22/20
Ziopharm Oncology announced the appointment of James Huang to the Company's Board of Directors. Huang is currently a Managing Partner at Kleiner Perkins Caufield & Byers China and has founded and financed several innovative life sciences companies. He is also Founding Partner of Panacea Venture, which formed TriArm Therapeutics, the funding partner for Ziopharm's joint venture, Eden BioCell.
Ziopharm took 'important step' with start of CAR-T study, says Lake Street » 09:1107/1007/10/20
Lake Street analyst…
Lake Street analyst Thomas Flaten said a combination of planning issues, manufacturing optimization and the pandemic delayed initiation of Ziopharm's Phase 1 study of its CD19 CAR-T program and he sees the start of the trial as "an important step, while adding that "results will ultimately determine the success of the study." Flaten, who acknowledges that "it will be some time until data is available," keeps a Buy rating and $7 price target on Ziopharm shares.
Fly Intel: Pre-market Movers » 09:0607/1007/10/20
GILD, ZIOP, ALV, MATX, GBX, SLP, BYND, SC, FSLY, RIG, CNTG
Check out this morning's…
Fly Intel: After-Hours Movers » 19:0207/0907/09/20
SLP, PSMT, MATX, ZIOP, IART, WDFC, FC, KERN
Check out this evening's…
Ziopharm initiates Phase 1 trial evaluating CD19-specific CAR-T » 16:1607/0907/09/20
Ziopharm Oncology announced the initiation of a phase 1 clinical trial to evaluate CD19-specific CAR-T, using its Rapid Personalized Manufacturing technology, as an investigational treatment for patients with relapsed CD19+ leukemias and lymphomas. The trial is now open for enrollment at The University of Texas MD Anderson Cancer Center. In this trial, the company utilizes its non-viral Sleeping Beauty genetic engineering technology to infuse CAR-T the day after electroporation. Ziopharm's RPM CD19-specific CAR-T therapy results from the stable, non-viral insertion of DNA into the genome of resting T cells to co-express the chimeric antigen receptor, membrane-bound IL-15 and a safety switch.
Ziopharm doses first patient with DIPG in Ad-RTS-hIL-12 study » 08:4207/0807/08/20
Ziopharm announced that…
Ziopharm announced that the first patient with diffuse intrinsic pontine glioma, or DIPG, has been dosed in its phase 1/2 study of Ad-RTS-hIL-12 with veledimex for the treatment of pediatric brain tumors.
|Over a month ago|
Unusual call flow in option market yesterday » 07:3506/2406/24/20
AAPL, ETSY, ZIOP
Notable call activity was…
Notable call activity was cited Tuesday in Apple (AAPL), Etsy (ETSY), and Ziopharm (ZIOP).
Calls lead puts 11:1 in Ziopharm Oncology » 10:1006/2306/23/20
Calls lead puts 11:1 in…
Calls lead puts 11:1 in Ziopharm Oncology. Shares up 10c, or nearly 3%, to $3.66 this morning with 1400 calls trading early, vs 120 puts and July 4 calls seeing most of the flow, including a 15c buyer of 522, followed by 20c for another 500.
Ziopharm completes enrollment of Phase 2 trial of IL-12 with Libtayo » 08:3206/2206/22/20
Ziopharm Oncology (ZIOP)…
Ziopharm Oncology (ZIOP) announced that 36 subjects have been enrolled in the phase 2 clinical trial evaluating Ad-RTS-hIL-12 with veledimex in combination with the PD-1 inhibitor Libtayo for the treatment of recurrent or progressive glioblastoma in adults. Subjects in this multi-center trial were enrolled from seven hospitals specializing in the treatment of brain cancers across the United States. Ziopharm's Controlled IL-12 platform is an investigational gene therapy designed to induce and control the production of human interleukin 12, a master-regulator of the immune system. In the setting of rGBM, the Company is leveraging the anti-tumor effects for Controlled IL-12 as a monotherapy and in combination with PD-1 inhibitors. Clinical data supporting the combination of Controlled IL-12 and a PD-1 inhibitor were initially published in Science Translational Medicine. Data from serial biopsies in patients with rGBM revealed that Controlled IL-12 results in the sustained influx of activated T cells and upregulation of PD-1 expression, providing a compelling rationale for this combination. Recently, additional data from a phase 1 trial were presented at the American Society of Clinical Oncology 2020 virtual meeting showing Controlled IL-12 in combination with a PD-1 inhibitor had a favorable safety profile and preliminary signs of anti-tumor efficacy. The open-label, single-arm phase 2 trial is designed to examine Controlled IL-12 in combination with cemiplimab in 36 patients with rGBM, with the primary endpoints being safety and efficacy. Patients with rGBM scheduled for resection, who have not been treated previously with immune checkpoint inhibitors, received Ad-RTS-hIL-12 intratumorally at the time of surgical resection plus 20 mg of veledimex, an oral activator of Ad-RTS-hIL-12, daily for 14 days. Patients will also receive cemiplimab intravenously every three weeks until documented progression or withdrawal from the study. Trial investigators may enroll additional patients currently in screening. In November 2018, Ziopharm and Regeneron entered a clinical supply agreement to evaluate combination therapy of Ziopharm's Controlled IL-12 with Regeneron's (REGN) PD-1 antibody cemiplimab to treat patients with rGBM.
Ziopharm initiated with a Buy at Jefferies » 06:0006/1906/19/20
Jefferies analyst Chris…
Jefferies analyst Chris Howerton initiated coverage of Ziopharm Oncology with a Buy rating and $7 price target. While the company has a long history, it has a "new story with exciting" gene and cellular therapies for oncology, Howerton tells investors in a research note. The analyst sees "substantial upside" from clinical success in either of Ziopharm's programs, TCR-T in solid tumors and Ad-RTS-hIL12 in recurrent glioblastoma.